-

European Patent Office Grants OmniGuide with patent for its Laparoscopic Handpiece for FlexAssure CO2 Flexible Instruments and Fibers

BOSTON--(BUSINESS WIRE)--The European Patent Office granted OmniGuide with a new patent for its Laparoscopic Handpiece for FlexAssure CO2 Flexible Instruments (Patent Number 3193695).

Laparoscopy is a surgical approach that allows a surgeon to access the inside of the human body without making large incisions. These procedures are widely adopted worldwide for their patient benefits including smaller surgical scars, quicker recovery, and decreased post procedure pain.

OmniGuide FlexAssure CO2 Flexible Instruments are utilized in thousands of surgical procedures including Urology, Gynecology, ENT, and Neurology as well as with handheld, laparoscopic, and surgical robots.

“We are pleased that the European Patent Office has granted this new patent, in line with our continuous investment in minimally invasive surgery and New Product Development” stated Robert Allen, OmniGuide CFO and LISA Laser Products Managing Director “OmniGuide has the widest portfolio of CO2 Flexible Instruments and Fibers, uniquely designed to meet minimally invasive surgical needs. Our investment in expanding and protecting our Intellectual Property is paramount for OmniGuide’s long term success.”

“Continuous innovation in CO2 Laser Flexible Instruments and Fibers is one of OmniGuide’s growth pillars” said Giorgio Brusa Global VP Marketing OmniGuide Holding “with zero intra-abdominal instrument breakage in over 24,000 procedures OmniGuide FlexAssure CO2 Flexible Instruments are trusted by clinical centers of excellence for their Laparoscopic and Robotic surgical patients”.

Contacts

OmniGuide Holdings
customerservice@omni-guide.com

OmniGuide Holdings


Release Versions

Contacts

OmniGuide Holdings
customerservice@omni-guide.com

More News From OmniGuide Holdings

German Federal Ministry of Education and Research awards grants to fund a clinical trial for LISA Laser innovated “novel treatment of urolithiasis”

GÖTTINGEN, Germany--(BUSINESS WIRE)--On the 26th of August 2022, the German Federal Ministry of Education and Research selected a “novel approach for the treatment of urolithiasis” for funding (Grant No. 13GW0628). Urolithiasis (urinary stone formation) is a common disease affecting about 12% of the global population. Consequently, urolithiasis is a widespread disease with significant socioeconomic impact and is relevant to healthcare in terms of society and health policy. LISA Laser Products G...

OmniGuide Holdings Receives FDA Clearance for RevoLix™ HTL Hybrid Thulium Laser for the treatment of BPH and Stones

BILLERICA, Mass.--(BUSINESS WIRE)--OmniGuide Holdings (OGH) Today, the U.S. Food and Drug Administration cleared RevoLix™ HTL a family of pulsed and continuous wave Thulium YAG lasers is the foundation of RevoLix Therapy for urology patients undergoing BPH and Stone Management procedures. “The FDA's clearance reflects our confidence in our unique RevoLix™ HTL therapy and our efforts into surgical laser innovation, setting new standards in patients' safety,” said Dr. Samir Lamrini Global Directo...

OmniGuide Receives 510(k) FDA Clearance for OTO-U Otology CO2 Surgical Fiber

BILLERICA, Mass.--(BUSINESS WIRE)--OmniGuide Holdings, a global healthcare technology leader in the design and delivery of innovative solutions for medical and surgical procedures, announces the commercial launch of the NEW OTO-U CO2 Laser System Fiber, designed for ENT and Otology Surgeons. “OmniGuide continues to put patients first, invest in R&D, and deliver to the quality expected from our global brand. We understand the need for an everyday CO2 surgical fiber to complement our Flexible...
Back to Newsroom